Massachusetts General Hospital

Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress

Retrieved on: 
Giovedì, Maggio 9, 2024
University, Inflammation, Biomarker, Nebraska Medicine, EGFR, Patient, Kidney transplantation, ATC, Faculty, Massachusetts General Hospital

IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company will participate in the American Transplant Congress (ATC) taking place in Philadelphia, PA from June 1-5, 2024.

Key Points: 
  • IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company will participate in the American Transplant Congress (ATC) taking place in Philadelphia, PA from June 1-5, 2024.
  • The Company will present a poster that features updated data from Eledon’s ongoing open-label Phase 1b trial and open-label extension study evaluating tegoprubart for the prevention of rejection in patients undergoing kidney transplantation.
  • Details on the poster presentation are below:
    Title: Biomarkers of Inflammation and eGFR in an Ongoing Phase 1B Study of an Anti-CD40L Antibody Tegoprubart, for the Prevention of Rejection in Kidney Transplant
    Presenter: Steve Perrin, Ph.D., President and Chief Scientific Officer, Eledon Pharmaceuticals
    The Company will also sponsor a satellite symposium at ATC titled: Blazing a path towards “Total Success” in Solid Organ Transplantation, to be held on Sunday, June 2, at 12:15pm ET.
  • Faculty include, Flavio Vincenti, M.D., University of California San Francisco, Diane Cibrik, M.D., University of Kansas Health System, Allan Kirk, M.D., Duke University School of Medicine, Jay Fishman, M.D., Massachusetts General Hospital, Klemens Budde, M.D., Charité Universitätsmedizin Berlin and Roslyn Mannon, M.D., University of Nebraska Medical Center.

Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Retrieved on: 
Martedì, Maggio 7, 2024
FDA, Amyloid beta, Part, Total, PIPE, CDER, Transferrin receptor, Nerve, BBB, CSF, Biomarker, Gamma, Enzyme replacement therapy, Traffic barrier, Hunting, OTV, PTV, Food, MGH, IDS, Conference, MAPT, ALS, Therapy, Cerebrospinal fluid, SAN, MPS II, Hospital, Safety, AFL, SGSH, UC, Alpha-synuclein, LUMA, SNCA, Clinical trial, Glycogen storage disease, Neurodegenerative disease, MPS, COMPASS, Patient, Alfa, Acquisition, ETV, ATV, Hunter syndrome, Sanofi, Massachusetts General Hospital, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the first quarter ended March 31, 2024, and provided business highlights.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the first quarter ended March 31, 2024, and provided business highlights.
  • There was no collaboration revenue for the quarter ended March 31, 2024, compared to $35.1 million for the quarter ended March 31, 2023.
  • Total research and development expenses were $107.0 million for the quarter ended March 31, 2024, compared to $128.8 million for the quarter ended March 31, 2023.
  • General and administrative expenses were $25.2 million for the quarter ended March 31, 2024, compared to $27.1 million for the quarter ended March 31, 2023.

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Retrieved on: 
Lunedì, Maggio 6, 2024
Idiopathic pulmonary fibrosis, FVC, Investment, Hospital, Safety, Primary sclerosing cholangitis, Research, IPF, Collagen, Trial of the century, PET, Acceleration, DMD, Tumor microenvironment, PSC, European, Novartis, Week, Therapy, Vital capacity, Muscular dystrophy, Patient, TGF, Fibrosis, Cirrhosis, Integrin, Duchenne muscular dystrophy, Biomarker, Ethics committee, Massachusetts General Hospital, ELF, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage clinical biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported first quarter 2024 financial results.

Key Points: 
  • As part of the adaptive Phase 2b/3 implementation, the Phase 2b portion of BEACON-IPF was upsized from 267 patients to 360 patients.
  • Enrollment is progressing and we expect to complete enrollment of the upsized Phase 2b study expected in the first quarter of 2025.
  • The increase was due to higher operating expenses coupled with a decrease in collaboration revenues under the Novartis agreement during the quarter.
  • As of March 31, 2024, the Company had cash, cash equivalents and short-term investments of $483.9 million.

Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine

Retrieved on: 
Lunedì, Maggio 6, 2024
FDA, Bangladesh Technical Education Board, JAMA, Hospital, NIH, Safety, Nausea, Sleep, American Medical Association, MD, Trial of the century, Doctor of Philosophy, Research, Nicotine, Cytisine, Smoking, Treatment, Principal, COVID-19, Fatigue, Headache, Odds ratio, Harvard Medical School, Internal medicine, Upper respiratory tract infection, Clinical trial, Anxiety, Massachusetts General Hospital, Journal, Prevalence, Ageing

SEATTLE and VANCOUVER, British Columbia, May 06, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced publication of the ORCA-V1 trial results in the Journal of the American Medical Association (JAMA) Internal Medicine. ORCA-V1 evaluated the efficacy and safety of 3 mg cytisinicline dosed three times daily for 12 weeks compared to placebo in 160 non-smoking adults who used e-cigarettes or nicotine vapes and wanted to quit e-cigarettes. All participants received behavioral support for vaping cessation.

Key Points: 
  • SEATTLE and VANCOUVER, British Columbia, May 06, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced publication of the ORCA-V1 trial results in the Journal of the American Medical Association (JAMA) Internal Medicine .
  • As reported today, the ORCA-V1 trial demonstrated that biochemically confirmed continuous vaping abstinence during the last 4 weeks of treatment, the primary outcome measure, was significantly higher for cytisinicline treatment compared to placebo.
  • During the 12-week study treatment, the past seven-day prevalence of vaping abstinence at each week was consistently higher in the cytisinicline group than the placebo group.
  • Achieve plans to conduct an End-of-Phase 2 Meeting with the FDA later this year to discuss future clinical trial requirements to pursue an indication for vaping cessation.

Nvelop Therapeutics to Share the First Preclinical Data from its Novel, Humanized Particle Platform for In Vivo Delivery of Genetic Cargoes at the ASGCT Annual Meeting

Retrieved on: 
Giovedì, Maggio 9, 2024
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Other Science, Medical Devices, Research, Surgery, Genetics, Science, CRISPR, Viral, Safety, Gene editing, Cell, Gene, Society, Therapy, Massachusetts General Hospital, Vaccine

Nvelop Therapeutics , a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of therapeutic cargo, today announced the presentation of new preclinical data from its DLVR-M platform at the 27th annual meeting of the American Society of Gene & Cell Therapy (ASGCT) in Baltimore.

Key Points: 
  • Nvelop Therapeutics , a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of therapeutic cargo, today announced the presentation of new preclinical data from its DLVR-M platform at the 27th annual meeting of the American Society of Gene & Cell Therapy (ASGCT) in Baltimore.
  • These data are the first from its DLVR-M platform, one of Nvelop’s two in vivo-validated platforms currently being developed to enable efficient and cell-specific delivery of a broad set of therapeutic cargoes to treat a wide range of genetic diseases.
  • DLVR-M has a distinct mechanism for loading cargoes within the particles, which does not rely on viral-derived proteins.
  • “This represents an important advance for the delivery of genetic medicines with intricately engineered particles that have the potential to be fully humanized.

New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy

Retrieved on: 
Domenica, Maggio 5, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Hope, Hospital, UTUC, American Urological Association, RFS, Recurrence, MD, IQR, Disease, Patient, Clutch (eggs), Mitomycins, Neoplasm, Massachusetts General Hospital, Central Sindical Angolana, Medical imaging

Among the 30% of the complete responders who received maintenance therapy, RFS at 24 months was 100%, vs. 61% for those who did not receive maintenance therapy.

Key Points: 
  • Among the 30% of the complete responders who received maintenance therapy, RFS at 24 months was 100%, vs. 61% for those who did not receive maintenance therapy.
  • “Notably, there seems to be no discernible difference in disease recurrence based on tumor characteristics or timing of administration, including primary chemoablation or post-endoscopic ablation.
  • Data was collected from 15 centers on patients treated with JELMYTO for upper tract urothelial cancers (UTUC).
  • Recurrence-free survival was calculated in 53 patients with LGTa disease at baseline who had no evidence of disease following JELMYTO induction.

Tyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. to its Board of Directors

Retrieved on: 
Martedì, Maggio 7, 2024
Stanford University, University, FGFR, Disorder, Fibroblast growth factor receptor, Hospital, NDA, QED, Achondroplasia, Hematology, Bile duct, Drug, Research and development, MAA, Yale University, RET, Growth, Duke University, Biotechnology, Therapy, Faculty, Osteochondrodysplasia, Harvard Medical School, Multiple sclerosis, Biology, Drug development, Drug discovery, Liver cancer, Bristol Myers Squibb, Massachusetts General Hospital, Puma Biotechnology, Pharmaceutical industry

and S. Michael Rothenberg, M.D., Ph.D. as independent directors, and the resignation of Isan Chen, M.D.

Key Points: 
  • and S. Michael Rothenberg, M.D., Ph.D. as independent directors, and the resignation of Isan Chen, M.D.
  • "Susan and Michael's impressive careers will provide TYRA with valuable guidance as we advance our potential next-generation precision candidates toward people in need.
  • In connection with these appointments, Dr. Chen, who has served as a director since June 2020, has resigned from the TYRA Board.
  • "On behalf of the Board, I want to thank Isan for his many contributions to TYRA.

DR. KIYA MOVASSAGHI ASSUMES PRESIDENCY OF THE AESTHETIC SOCIETY, CHARTING A COURSE FOR GLOBAL PARTNERSHIPS AND ADVANCING AESTHETIC EDUCATION

Retrieved on: 
Domenica, Maggio 5, 2024
Education, General surgery, Breast, Resident, Weight loss, Partnership, NYU, University, Face, Rhinoplasty, Woman, DMD, Large, Abdominoplasty, Navy, Executive Committee, Memorandum, Mount Sinai Hospital, Harvard Medical School, Fifth Avenue, Emory University, Royal college, Microsoft, Safety, Publication, Plastic surgery, Division, The Hamptons, School, Society, Patient, Medical school, University Health Network, Elective surgery, FACS, Annual general meeting, Massachusetts General Hospital, Women's College Hospital, Dentistry

VANCOUVER, BC, May 5, 2024 /PRNewswire/ -- The Aesthetic Society proudly announces the appointment of Dr. Kiya Movassaghi, a board-certified plastic surgeon from Eugene, OR, as the President of The Aesthetic Society. Dr. Movassaghi's leadership will focus on strategically fortifying The Society's position as the global leader in education and innovation in the aesthetic marketplace.

Key Points: 
  • Dr. Movassaghi's leadership will focus on strategically fortifying The Society's position as the global leader in education and innovation in the aesthetic marketplace.
  • "I am honored to assume the presidency of The Aesthetic Society," said Dr. Movassaghi.
  • Global outreach through Memorandums of Understanding (MOUs) will be instrumental in shaping our engagement and alliances among our international colleagues.
  • A 1995 graduate of Harvard Medical School, Dr. Movassaghi completed a three-year plastic surgery residency at the Harvard Combined Plastic Surgery Program.

Latus Launches with State-of-the-Art Gene Therapy Development Technologies, Two Lead Product Candidates, and an Initial $54 Million in Series A Financing

Retrieved on: 
Giovedì, Maggio 2, 2024
Biotechnology, Professional Services, Health, General Health, Pharmaceutical, Other Science, Research, Genetics, Science, Clinical Trials, Finance, Doctor of Philosophy, CNS, SVP, Translational medicine, MIT, Genzyme, Cochlea, Hereditary Disease Foundation, Harvard Medical School, Toxicity, HTT, Therapy, Merck, CLN2, Hospital, Safety, Biomedical Research, Samsung Biologics, CHOP, Samsung C&T Corporation, AAV, Koch Institute, Gene expression, Central nervous system, NHP, Program management, Cell, DSM-IV codes, Patient, Gene, Society, Einstein Medical Center Philadelphia, Annual general meeting, Massachusetts General Hospital, Pharmaceutical industry

Latus Bio, Inc. (“Latus”), a biotechnology company developing novel gene therapy candidates for disorders of the central nervous system (CNS), today announced its launch and an initial close of $54 million in Series A financing.

Key Points: 
  • Latus Bio, Inc. (“Latus”), a biotechnology company developing novel gene therapy candidates for disorders of the central nervous system (CNS), today announced its launch and an initial close of $54 million in Series A financing.
  • These limitations have led to the reliance on high-dose injections that cause off-target toxicity and difficulties in scalable manufacturing.
  • The Company’s management team is composed of experienced and respected leaders in gene therapy and neuroscience.
  • Her address will showcase the Company's progress and the vast potential of its technology to solve unmet needs in CNS gene therapy.

SREE CHAGUTURU, MD, CHIEF MEDICAL OFFICER, CVS HEALTH, BECOMES CHAIR OF THE AMERICAN TELEMEDICINE ASSOCIATION BOARD OF DIRECTORS

Retrieved on: 
Venerdì, Maggio 3, 2024
Nexus, Alpert Medical School, CVS, DNP, FAAN, Mass, Hospital, Policy, Health, PBM, Internal medicine, MD, Brown University, CVS Health, Patient safety, Telehealth, Medicine, CVS Caremark, American Telemedicine Association, Biology, Mass General Brigham, ATA, Massachusetts General Hospital, COVID-19

WASHINGTON, May 3, 2024 /PRNewswire/ -- The American Telemedicine Association (ATA) today announced that Sree Chaguturu, MD, has become Chair of the Board of Directors.

Key Points: 
  • WASHINGTON, May 3, 2024 /PRNewswire/ -- The American Telemedicine Association (ATA) today announced that Sree Chaguturu, MD, has become Chair of the Board of Directors.
  • Dr. Chaguturu is Executive Vice President and Chief Medical Officer, CVS Health®, where he leads the enterprise medical affairs organization spanning across all segments: Aetna®, CVS HealthSpire®, CVS Pharmacy®.
  • Dr. Chaguturu becomes ATA Chair of the Board beginning immediately, succeeding Kristi Henderson, DNP, FAAN, CEO, Confluent Health.
  • Before joining CVS Health, Sree was chief population health officer of Mass General Brigham, the largest health care system in Massachusetts.